# Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma

> **NCT05004064** · PHASE2 · RECRUITING · sponsor: **University College, London** · enrollment: 48 (estimated)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Acalabrutinib
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT05004064
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-30
- **Primary completion:** 2026-11-30
- **Final completion:** 2028-12-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05004064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05004064, "Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05004064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*